Leerink Partners analyst Paul Matteis notes shares of Neurocrine Bio. (NASDAQ: NBIX) are down 18% over the past few weeks ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE